NEW YORK, April 28, 2004 (PRIMEZONE) -- The following information and opinions are from Warren B. Eugene, President of Amigula, Inc.:
Amigula Incorporated (Pink Sheets:AMJL) -- the World's First Publicly traded Medical Marijuana Company -- announced today that the company supports the article in the NY Times on April 26th 2004 by Eric Schlosser.
Warren B. Eugene, Amigula's President, commented today: Eric Schlosser is an excellent reporter. He seemed to understand the issues.
In my opinion, the Forbes article on our company is nothing more than slanted, biased writing: unprofessional, poorly written, with some quacky quick wit, some childish puns, and silly one-liners.
Forbes failed to do anything but critique a developing 6-month-old company with original ideas and an altruistic, creative, and caring spirit. Shame on them. Children and adults of all ages are suffering severe pain in hospitals the world over. This is a serious First Amendment issue; the freedom to choose one's own medicine is at stake. The writer should not have been so flippant in my opinion -- especially with something as important as this issue -- whilst millions of our loved ones suffer every day in pain and agony from MS, Chemotherapy treatment, Glaucoma, Epilepsy, Arthritis, Aids, and Nausea. It is an affront to decent human behavior. I'm appalled and disappointed at Forbes.
Amigula has met on 2 separate occasions with Montel Williams and his associates. Mr. Williams is a world class, celebrated author, philanthropist, TV personality and inspirationalist. He is a remarkable being. States Warren Eugene, I was honored and privileged to have been able to meet Montel Williams and listen and learn from him. I would love to work with him. I invited him to join us and champion the cause and to co-found and develop the company with me.
Amigula had the privilege of meeting the celebrated and renowned Howard Rubinstein of Howard Rubinstein and Associates. Mr. Rubinstein offered some sound advice in that meeting.
Mr. Rubenstein granted presentation time to us. I would be honored if he would accept our company and cause and represent us.
Amigula, Inc. has had ongoing relations with several celebrity management groups.
Amigula Inc. has received contractual documentation from Gem Funds of New York, and is in continued negotiation with them. As they have been willing to provide a convertible debenture to the company for up to $3 million dollars, partially based on Amigula Inc. filing to become reporting and registration submissions. As well, Gem Funds have extended to Amigula Inc., should they become traded on the London AIM, a line of credit for $25,000,000 pounds sterling. The provision includes cross listing the company on the AIM exchange in London from the current OTC. Amigula has yet to sign the contract but is considering the offer.
Amigula is intent on seeking dual listing in multiple markets. Amigula anticipates that several international markets may allow for the distribution of medical marijuana and that the company intends to be ready to supply those markets if and when they become available.
Press releases, such as this one, are the only reliable sources of information on Amigula, Inc.